menu ☰
menu ˟

Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: Metabolic and immunologic features at baseline identify a subgroup of responders

08 Jul 2013

Kevan C Herold, Stephen E Gitelman, Mario R Ehlers, Peter A Gottlieb, Carla J Greenbaum, William Hagopian, Karen D Boyle, Lynette Keyes-Elstein, Sudeepta Aggarwal, Deborah Phippard, Peter H Sayre, James McNamara, Jeffrey A Bluestone, the AbATE Study Team
Jul 8, 2013; 0:1303451-130345
Original Research

Date: 
8 July 2013

Click here to view the full article which appeared in Clinical Diabetes